We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Genetic Technologies Ltd (GENE) ADR Each Rep 600 Ord Shares (Spons)

Sell:$1.77 Buy:$1.79 Change: $0.02 (1.14%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.77
Buy:$1.79
Change: $0.02 (1.14%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.77
Buy:$1.79
Change: $0.02 (1.14%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company focuses on the development and commercialization of genetic risk assessment technology for contracting cancer and other chronic diseases. The Company operates through two geographic segments: Australia and United states of America (USA). Australia segment is the home country of the parent entity and the location of the Company's genetic testing and licensing operations. USA segment is the home of Phenogen Sciences Inc. and GeneType Corporation. The Company’s products include GeneType for Breast Cancer is a test that can determine a woman's risk of developing sporadic breast cancer over a period of time; GeneType for Colorectal Cancer is a test that can determine a patient's risk of developing colorectal cancer over a period of time. The Company focuses on development its Germline testing division for hereditary testing.

Contact details

Address:
60-66 Hanover St, Fitzroy
MELBOURNE
3065
Australia
Telephone:
+61 (3) 94151135
Website:
https://www.gtglabs.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GENE
ISIN:
US37185R3075
Market cap:
$26.25 million
Shares in issue:
8.26 billion
Sector:
Life Sciences Tools & Services
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Peter Rubenstein
    Chairman of the Board
  • Simon Morriss
    Chief Executive Officer
  • Michael Tonroe
    Chief Financial Officer, Company Secretary
  • Mark Ostrowski
    President of Phenogen Sciences Inc
  • Stan Sack
    Chief Operating Officer
  • Jerzy Muchnicki
    Chief Medical officer, Executive Director
  • Richard Allman
    Scientific Director
  • M. Luisa Ashdown
    Director of Global Licensing and Intellectual Property
  • Susan Gross
    Senior Medical Director
  • Diana Newport
    Quality and Business Operations Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.